USFDAJul 13, 2026, 05:39 PM
Biogen's LEQEMBI IQLIK FDA Approved for At-Home Initiation Dosing
AI Summary
Biogen Inc. and Eisai Co., Ltd. announced that the U.S. FDA has approved a supplemental Biologics License Application for LEQEMBI IQLIK (lecanemab-irmb), a once-weekly subcutaneous injection for the initiation dose in early Alzheimer's disease. This approval introduces a convenient at-home dosing option via an autoinjector, offering flexibility for patients and care partners. The U.S. launch of the initiation dose is anticipated in late August 2026.
Key Highlights
- FDA approved LEQEMBI IQLIK (lecanemab-irmb) for early Alzheimer's disease.
- Approved as a once-weekly subcutaneous injection for initiation dosing.
- Allows convenient at-home administration via an autoinjector.
- Initiation regimen is 500 mg once weekly, delivered as two 250 mg injections.
- Maintenance dosing is 360 mg once weekly after 18 months of treatment.
- U.S. launch of the initiation dose is planned for late August 2026.
- Clinical data showed equivalent exposure and similar efficacy to IV administration.
- 94% of patients and care partners found the autoinjector easy to use.
Price Impact
More from BIIB